Seattle Genetics Looking To Improve, Replace Standards Of Care
Executive Summary
Seattle Genetics is transitioning from a one-product to multi-product company while growing its established Adcetris franchise. New studies are coming for three additional antibody-drug conjugates aimed at solid tumors.
You may also be interested in...
Keeping Track: Yupelri Is Latest Novel Drug Approved, But Bad News For Biosimilars
The latest drug development news and highlights from our US FDA Performance Tracker.
Breakthrough Status Arrives Late In Development Of Yervoy+Opdivo, Enfortumab Vedotin And Pedmark
US FDA's latest BTD awards go to Seattle Genetics and Astellas' antibody-drug conjugate for immunotherapy-experienced urothelial cancer, Fennec's supportive care product to reduce cisplatin ototoxicity in pediatric cancer patients, and Bristol's double immunotherapy combo in MSI-H colorectal cancer.
Seattle Genetics Says Adcetris Sets New Standard In Frontline Lymphoma
The market for a new FDA-approved indication in frontline classical Hodgkin lymphoma could be worth $650m to $750m, some analysts say.